Periprocedural myocardial injury during elective percutaneous coronary intervention: Is it important and how can it be prevented?

Heart

Volumn 96, Issue 10, 2010, Pages 736-740

  Cuculi, F ^a   Lim, C C S ^a   Banning, Adrian P ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; NICARDIPINE; PLACEBO; PRASUGREL; PROPRANOLOL; TICAGRELOR; TROPONIN; VERAPAMIL;

CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG DOSE COMPARISON; ELECTIVE SURGERY; HEART MUSCLE INJURY; HUMAN; LOADING DRUG DOSE; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; REVIEW; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; HEART INJURIES; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS;

EID: 77952640181     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.186189     Document Type: Review

References (66)

1. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-251
2. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-2538
3. Oh JK, Shub C, Ilstrup DM, et al. Creatine kinase release after successful percutaneous transluminal coronary angioplasty. Am Heart J 1985;109:1225-1231 (Pubitemid 16119635)
4. Harrington RA, Lincoff AM, Califf RM, et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol 1995;25:1693-1699
5. Abdelmeguid AE, Topol EJ, Whitlow PL, et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-1536
6. Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002;106:1205-1210 (Pubitemid 34988637)
7. Kini A, Marmur JD, Kini S, et al. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course: implications for early discharge after coronary intervention. J Am Coll Cardiol 1999;34:663-671 (Pubitemid 29436169)
8. Stone GW, Mehran R, Dangas G, et al. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001;104:642-647 (Pubitemid 32738516)
9. Tardiff BE, Califf RM, Tcheng JE, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. J Am Coll Cardiol 1999;33:88-96.
10. Nienhuis MB, Ottervanger JP, Dikkeschei B, et al. Prognostic importance of troponin T and creatine kinase after elective angioplasty. Int J Cardiol 2007;120:242-247 (Pubitemid 47053880)
11. Ricciardi MJ, Davidson CJ, Gubernikoff G, et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J 2003;145:522-528 (Pubitemid 36390500)
12. Selvanayagam JB, Porto I, Channon K, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 2005;111:1027-1032 (Pubitemid 40354521)
13. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1406-1411 (Pubitemid 37267281)
14. Prasad A, Singh M, Lerman A, et al. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 2006;48:1765-1770 (Pubitemid 44648624)
15. Nienhuis MB, Ottervanger JP, Bilo HJ, et al. Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 2008;71:318-324 (Pubitemid 351428148)
16. Testa L, Van Gaal WJ, Biondi Zoccai GG, et al. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM 2009;102:369-378
17. Prasad A, Gersh BJ, Bertrand ME, et al. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009;54:477-486
18. Barnathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987;76:125-134 (Pubitemid 17093200)
19. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-1719
20. Lembo NJ, Black AJ, Roubin GS, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990;65:422-426
21. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. the task force for percutaneous coronary interventions of the european society of cardiology. Eur Heart J 2005;26:804-847
22. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089 (Pubitemid 26120185)
23. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-1671
24. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533 (Pubitemid 32772726)
25. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;294:1224-1232 (Pubitemid 41352110)
26. Moore RK, Lowe R, Grayson AD, et al. A study comparing the incidence and predictors of creatine kinase MB and troponin T release after coronary angioplasty. does clopidogrel preloading reduce myocardial necrosis following elective percutaneous coronary intervention? Int J Cardiol 2007;116:93-97
27. Szuk T, Gyongyosi M, Homorodi N, et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. Am Heart J 2007;153:289-295 (Pubitemid 46096860)
28. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420
29. Steinhubl SR, Berger PB, Brennan DM, et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006;47:939-943 (Pubitemid 43312753)
30. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005;111:2099-2106 (Pubitemid 40577905)
31. Widimsky P, Motovska Z, Simek S, et al. Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J 2008;29:1495-1503
32. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015 (Pubitemid 350106708)
33. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057
34. Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009;119:2758-2764
35. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221-231 (Pubitemid 47069129)
36. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33. (Pubitemid 43005160)
37. Dumaine R, Borentain M, Bertel O, et al. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch Intern Med 2007;167:2423-2430 (Pubitemid 350258448)
38. Diez JG, Medina HM, Cheong BY, et al. Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention. Tex Heart Inst J 2009;36:98-103.
39. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008;359:688-696
40. Feldman DN, Wong SC, Gade CL, et al. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents. Am Heart J 2007;154:695-701. (Pubitemid 47429595)
41. Anon Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422-1428
42. Anon Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. the EPILOG investigators. N Engl J Med 1997;336:1689-1696
43. Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232-238 (Pubitemid 38071801)
44. Mehilli J, Kastrati A, Schuhlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004;110:3627-3635 (Pubitemid 40003783)
45. Gumina RJ, Yang EH, Sandhu GS, et al. Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention. Mayo Clin Proc 2008;83:995-1001.
46. Bonz AW, Lengenfelder B, Strotmann J, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 2002;40:662-668
47. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study. Circulation 2005;111:1153-1159
48. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-2425 (Pubitemid 44522148)
49. Cuisset T, Frere C, Quilici J, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 2008;1:649-653
50. Saw J, Moliterno DJ. Contemporary use of antiplatelet therapies in percutaneous coronary interventions. Coron Artery Dis 2003;14:373-380 (Pubitemid 36994042)
51. Cuculi F, Radovanovic D, Eberli FR, et al. The impact of statin treatment on presentation mode and early outcomes in acute coronary syndromes. Cardiology 2008;109:156-162 (Pubitemid 351220515)
52. Mulukutla SR, Marroquin OC, Smith C, et al. Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury. Am J Cardiol 2004;94:1363-1366 (Pubitemid 39556203)
53. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-678 (Pubitemid 39056265)
54. Veselka J, Zemanek D, Hajek P, et al. Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study. Am J Cardiol 2009;104:630-633
55. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54:2157-2163
56. Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for reduction of myocardial damage during angioplasty) randomized trial. J Am Coll Cardiol 2009;54:558-565
57. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-1650
58. Takarada S, Imanishi T, Kubo T, et al. Effect of statin therapy on coronary fibrouscap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis 2009;202:491-497
59. Reimer KA, Rasmussen MM, Jennings RB. Reduction by propranolol of myocardial necrosis following temporary coronary artery occlusion in dogs. Circ Res 1973;33:353-363
60. Wang FW, Osman A, Otero J, et al. Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation 2003;107:2914-2919 (Pubitemid 36736632)
61. Uretsky BF, Birnbaum Y, Osman A, et al. Distal myocardial protection with intracoronary beta blocker when added to a Gp IIb/IIIa platelet receptor blocker during percutaneous coronary intervention improves clinical outcome. Catheter Cardiovasc Interv 2008;72:488-497
62. Gulmez O, Atar I, Ozin B, et al. The effects of prior calcium channel blocker therapy on creatine kinase-MB levels after percutaneous coronary interventions. Vasc Health Risk Manag 2008;4:1417-1422
63. Arora S, Alfayoumi F, Khawaja AT, et al. Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol 2009;32:315-320
64. Michaels AD, Appleby M, Otten MH, et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol 2002;14:299-302. (Pubitemid 34651235)
65. Desmet WJ, Dens J, Coussement P, et al. Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? the ADELINE pilot trial. ADEnosine Limit myocardial Necrosis. Heart 2002;88:293-295 (Pubitemid 34913518)
66. Hoole SP, Heck PM, Sharples L, et al. Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) study: a prospective, randomized control trial. Circulation 2009;119:820-827